One of the absorbed components in plasma, scopoletin, could target and regulate tyrosine kinases on fibroblast-like synoviocytes (FLS) to block NF-κB signaling, thereby attenuating the progression of RA [26]. Here, NFKB1 is linked to rheumatoid arthritis.